comparemela.com

Latest Breaking News On - Roche venture fund - Page 4 : comparemela.com

Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury

/PRNewswire/ Mission Therapeutics ("Mission" or the "Company"), a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, today.

United statesUnited kingdomSuhail nurbhaiPaul thompsonAnker lundemoseRoche venture fundDrug administrationMission therapeuticsIp groupPrnewswire mission therapeuticsInvestigational new drugAcute kidney injuryNorth americaChief executive officerChief medical officerChief scientific officer

IP : Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury -December 14, 2023 at 12:44 pm EST

14 Dec 2023 - Mission gains clearance from US FDA for Phase II trial of MTX652 after it receives official approval of its Investigational New Drug application .

United statesMary clarkStephen adamsPaul thompsonAnker lundemoseSuhail nurbhaiMission therapeutics ltdDrug administrationMission therapeuticsIp groupStrategic communicationsRoche venture fundInvestigational new drugAcute kidney injuryNorth americaChief executive officer

Mission Therapeutics granted MHRA Clinical Trial Authorisation (CTA) for MTX325 for the treatment of Parkinson s Disease

/PRNewswire/ Mission Therapeutics ("Mission" or the "Company"), a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, today.

United kingdomAnker lundemoseSuhail nurbhaiPaul thompsonPrnewswire mission therapeuticsCambridge universityIp groupMission therapeuticsRoche venture fundRegulatory agencyNature communicationsHarvard universityNature reviews drug discoveryChief executive officerChief scientific officerChief medical officer

NMD Pharma from Denmark secures €75M Series B to advance novel treatments for neuromuscular diseases

NMD Pharma from Denmark secures €75M Series B to advance novel treatments for neuromuscular diseases
arcticstartup.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from arcticstartup.com Daily Mail and Mail on Sunday newspapers.

United statesThomas holm pedersenLundbeckfonden biocapitalSabine dandiguianMike heffernanNovo holdingsRoche venture fundJeito capitalRoche ventureChief executive officerManaging partner

NMD Pharma Raises €75M in Series B Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Lundbeckfonden biocapitalThomas holm pedersenNovo holdingsRoche venture fundAarhus universityJeito capitalRoche ventureHolm pedersen

vimarsana © 2020. All Rights Reserved.